Back to Journals » Neuropsychiatric Disease and Treatment » Volume 12

Noradrenaline plays a critical role in the switch to a manic episode and treatment of a depressive episode

Authors Kurita M

Received 4 April 2016

Accepted for publication 17 June 2016

Published 20 September 2016 Volume 2016:12 Pages 2373—2380

DOI https://doi.org/10.2147/NDT.S109835

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Prof. Dr. Roumen Kirov

Peer reviewer comments 2

Editor who approved publication: Dr Taro Kishi

Video abstract presented by Masatake Kurita.

Views: 181

Masatake Kurita1–3

1Koutokukai Wakamiya Hospital, Yoshihara, Yamagata, 2Department of Cellular Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 3Department of Psychiatry and Behavioral Science, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan


Abstract: Although antidepressants may increase the risk of switching to mania in bipolar disorder (BD), clinicians have been using antidepressants to treat patients with bipolar depression. Appropriate treatments for bipolar depression remain controversial. In BD, antidepressants comprise a double-edged sword in terms of their efficacy in treating depression and the increased risk of switching. This review presents an important table outlining the benefit in terms of depression improvement and the risk of switching in the clinical setting. It also proposes strategies based on the characteristics of antidepressants such as their pharmacology, specifically the equilibrium dissociation constant (KD) of the noradrenaline transporter. This table will be useful for clinicians while considering benefit and risk. Antidepressants augmenting noradrenaline may be effective in bipolar depression. However, it is easily presumed that such antidepressants may also have a risk of switching to mania. Therefore, antidepressants augmenting noradrenaline will be the recommended treatment in combination with an antimanic agent, or they may be used for short-term treatment and early discontinuation. The corresponding medical treatment guidelines probably need to be reevaluated and updated based on biological backgrounds. From previous studies, we understand that the stability of noradrenaline levels is important for BD amelioration, based on the pathophysiology of the disorder. It is hoped that researchers will reevaluate BD by conducting studies involving noradrenaline.

Keywords: 3-methoxy-4-hydroxyphenylglycol, dopamine, homovanillic acid, brain-derived neurotrophic factor, biomarker, antidepressants, selective serotonin reuptake inhibitor, serotonin and noradrenaline reuptake inhibitor, tricyclic antidepressant, mood disorder

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Need for medication to complement catecholamines in smoking cessation of hardcore smokers

Kawai A, Kurita M, Nishino S, Hirata E, Sato T, Okubo Y

Neuropsychiatric Disease and Treatment 2017, 13:2419-2424

Published Date: 18 September 2017

Non-24-hour sleep–wake syndrome improved by low-dose valproic acid: a case report

Kurita M, Moriya T, Nishino S, Hirata E, Hirasawa N, Okubo Y, Sato T

Neuropsychiatric Disease and Treatment 2016, 12:3199-3203

Published Date: 13 December 2016

Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function

Takeyoshi K, Kurita M, Nishino S, Teranishi M, Numata Y, Sato T, Okubo Y

Neuropsychiatric Disease and Treatment 2016, 12:641-649

Published Date: 15 March 2016